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ABSTRACT
Aims/Introduction: Xanthine oxidoreductase (XOR) is an enzyme that catalyzes hypox-
anthine and xanthine to xanthine and uric acid, respectively. Plasma XOR activity has
recently been measured in humans. However, limited information is known about plasma
XOR activity in patients with type 2 diabetes mellitus, and its changes after short-term gly-
cemic control treatment.
Materials and Methods: We enrolled 28 Japanese patients (10 men/18 women) with
type 2 diabetes mellitus who were hospitalized to undergo medical treatment for dia-
betes. Plasma XOR activity, quantified using triple quadrupole mass spectrometry and liq-
uid chromatography, and other clinical parameters were examined at admission and
2 weeks after treatment during hospitalization. Changes in plasma XOR activity after treat-
ment during hospitalization and associated clinical parameters were assessed.
Results: At the time of admission, the median plasma XOR activity was 83.1 pmol/h/mL,
with a wide range of 14.4–1150 pmol/h/mL. Multiple regression analysis identified serum
aspartate transaminase and alanine transaminase levels as significant and independent fac-
tors correlating with the baseline plasma XOR. Two weeks of treatment during hospitaliza-
tion was associated with a significant decrease in plasma XOR activity. Changes in serum
aspartate transaminase were also the only significant and independent factor correlating
with changes in plasma XOR activity.
Conclusions: A close relationship was observed between plasma XOR activity and liver
transaminases in patients with type 2 diabetes mellitus, cross-sectionally, and also across
treatment during hospitalization.
INTRODUCTION
Hyperuricemia is closely associated with visceral fat accumula-
tion and related metabolic disorders, including diabetes mellitus,
hypertension, dyslipidemia, fatty liver and atherosclerotic car-
diovascular diseases (CVDs)1,2. Xanthine oxidoreductase (XOR)
is a rate-limiting enzyme that catalyzes the conversion of
hypoxanthine and xanthine to xanthine and uric acid,
respectively. XOR is also a pharmacological target of antihyper-
uricemic agents, such as allopurinol, febuxostat and topiroxo-
stat. Furthermore, previous studies have shown that XOR is
involved not only in the production of uric acid, but also in
the pathogenesis of CVD3–5. XOR is initially synthesized as
xanthine dehydrogenase, and its protein structure is converted
into xanthine oxidase under pathophysiological conditions, such
as tissue hypoxia6,7. Xanthine oxidase binds to negatively
charged glycosaminoglycans at the apical surface of vascular
endothelial cells8,9, and is well documented as a crucial sourceReceived 7 August 2020; revised 31 October 2020; accepted 16 November 2020
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of reactive oxygen species through the production of O2 and
H2O2, which indicates a possible causal role of this enzyme in
endothelial injury10,11.
We previously reported that the tissue distribution of XOR
gene expression differed between humans and rodents12.
Although XOR messenger ribonucleic acid expression in mur-
ine adipose tissue is similar to that in the liver, its messenger
ribonucleic acid expression in human tissues is limited in the
liver, lungs and gut. Consequently, the secretion of hypoxan-
thine from human adipocytes was dominant over that of xan-
thine and uric acid, whereas greater amounts of uric acid were
secreted from murine adipocytes than hypoxanthine and xan-
thine. The secretion of hypoxanthine from human adipocytes
and uric acid from murine adipocytes was previously shown to
increase under hypoxic conditions12.
Recent technological advances have made it possible to quan-
titatively measure the XOR activity in human plasma, despite
the presence of a much lower level of this enzyme than is pre-
sent in mouse plasma13. Plasma XOR activity was recently
shown to be associated with body mass index (BMI), home-
ostasis model assessment for insulin resistance (HOMA-IR),
liver dysfunction and hyperuricemia in cross-sectional studies,
on volunteers and participants subjected to annual health
checkups14,15. Findings from these previous studies show a pos-
sible link between high plasma XOR activity and metabolic dis-
orders, such as obesity and insulin resistance. However, limited
information is currently available on plasma XOR activity in
patients with type 2 diabetes mellitus, and also on its changes
after short-term treatments of glycemic control. Here, we show
a reduction in plasma XOR activity by glycemic control in
admitted patients with type 2 diabetes mellitus, and clinical
parameters associated with the change of plasma XOR activity.
METHODS
Study participants
The present study was carried out between December 2017 and
March 2019, enrolling patients with type 2 diabetes mellitus
aged between 20 and 75 years who were hospitalized in the
Division of Endocrinology & Metabolism, Osaka University
Hospital (Suita, Osaka, Japan) to improve glycemic control.
The diagnosis of type 2 diabetes mellitus was based on the cri-
teria of the World Health Organization National Diabetic
Group 2006 and/or current treatment for diabetes. The exclu-
sion criteria were: (i) patients for whom strict glycemic control
was inappropriate; for example, because of frequent episodes of
severe hypoglycemia and progressive diabetic retinopathy; (ii)
patients who had advanced diabetic nephropathy (serum crea-
tinine level >2.0 mg/dL); (iii) patients with acute infection, sev-
ere trauma or active cancer; (iv) patients in the pre- and
postoperative periods; and (v) patients who were not considered
to be eligible for the study based on the doctor’s assessment. A
total of 31 patients were enrolled in the present study
(MEDENGINE XOR study; XOR study based on medical-den-
tal-engineering [MEDENGINE] cooperation). Of these, three
patients taking XOR inhibitors for gout or asymptomatic hype-
ruricemia (two patients taking 10 mg/day and one taking
20 mg/day of febuxostat) were excluded from this study, and
the remaining 28 patients were included in the analysis. During
hospitalization, all the patients were treated with insulin, gluca-
gon-like peptide-1 analogs and/or oral glucose-lowering drugs
under dietary therapy to achieve the target levels of glycemic
control. A total of 29 volunteers without diabetes aged between
20 and 75 years were also examined in the present study.
This study was approved by the Human Ethics Committee
of Osaka University (no. 16374-6), and was carried out follow-
ing the Declaration of Helsinki. Written informed consent was
obtained from all of the study participants.
Measurements of clinical parameters and collection of blood
samples
Bodyweight and waist circumference (WC) at the level of the
umbilicus were measured in the standing position. Systolic and
diastolic blood pressure was measured in the sitting position
using a standard mercury sphygmomanometer. Blood samples
were collected in the morning after overnight fasting to mea-
sure plasma XOR activity, plasma glucose, C-peptide, glycated
hemoglobin (HbA1c; National Glycohemoglobin Standardiza-
tion Program), glycoalbumin, low-density lipoprotein choles-
terol, high-density lipoprotein cholesterol, triglycerides (TG),
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), γ-glutamyl transpeptidase (γ-GTP), lactate dehydroge-
nase, creatinine, uric acid, high-sensitivity C-reactive protein
(hs-CRP), acetoacetate and 3-hydroxybutyrate. Plasma adipo-
nectin concentrations were determined by an enzyme-linked
immunosorbent assay (human adiponectin enzyme-linked
immunosorbent assay kit; Otsuka Pharmaceutical Co. Ltd.,
Tokushima, Japan). The estimated glomerular filtration rate
was calculated using the formula proposed by the Japanese
Society of Nephrology16. These clinical parameters of the inpa-
tients with type 2 diabetes mellitus were examined at admission
and after 2 weeks of treatment during hospitalization. HOMA-
IR was calculated as (fasting insulin [μU/mL] × fasting plasma
glucose [mg/dL] / 405).
The maximum intima-media thickness of the common caro-
tid artery was measured using B-mode ultrasonography17. For
assessing the arterial stiffness, the brachial-ankle pulse wave
velocity was measured by an automatic form analyzer (BP-
203RPE II; Colin, Komaki, Japan).
Measurements of plasma XOR activity
Plasma XOR activity was quantified using triple quadrupole
mass spectrometry and liquid chromatography by detecting the
production of [13C2,
15N2]-uric acid from [
13C2,
15N2]-xanthine
as a substrate as reported previously13. Triple quadrupole mass
spectrometry and liquid chromatography comprised an LC sys-
tem (Shimadzu, Kyoto, Japan) and a QTRAP 4500 Mass Spec-
trometry System (SCIEX, Framingham, MA, USA) equipped
with an ESI interface. Calibration standard samples of [13C2,
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15N2]-uric acid were also measured, and production levels were
calculated from the calibration curve. Similar to the previous
study, XOR activities were expressed as pmol/h/mL. In this
method, the lower detection limit was 6.67 pmol/h/mL, and
coefficients of variation of the intra- and interassay were 6.5%
and 9.1%, respectively.
Measurements of hypoxanthine and xanthine
Hypoxanthine and xanthine concentrations in plasma were
measured as reported previously18. In brief, plasma samples
were obtained using blood collection tubes coated with
ethylenediaminetetraacetic acid-2K and placed in a cube cooler
within 1 min of collection. Within 30 min of collection, the
samples were centrifuged at 800 g at 4°C for 10 min. The
plasma samples were added to methanol containing [13C2,
15N2]-xanthine and [
13C3,
15N]-hypoxanthine as internal stan-
dards, and then centrifuged at 3,000 g at 4°C for 15 min. The
supernatant (40 µL) was diluted with distilled water (160 µL),
and concentrations of both the compounds were determined
by triple quadrupole mass spectrometry and liquid chromatog-
raphy (Nexera, SCIEX QTRAP 4500, SHIMADZU, Kyoto,
Japan).
Definitions
Hypertension was defined as blood pressure ≥140 mmHg and/
or diastolic blood pressure ≥90 mmHg, or the use of antihy-
pertensive agents. Dyslipidemia was defined as low-density
lipoprotein cholesterol ≥140 mg/dL, TG ≥150 mg/dL and/or
high-density lipoprotein cholesterol ≤ 40 mg/day, or the use of
antihyperlipidemic agents. CVD was defined as a history of
cerebrovascular disease, coronary artery disease and/or periph-
eral artery disease, which was determined by an ankle-brachial
pressure index <0.9.
Statistical analysis
All values are expressed as the mean – standard deviation or
the median (interquartile range [IQR]). Non-normally dis-
tributed variables were log-transformed before the analysis.
Relationships between two continuous variables were analyzed
using scatter plots and Pearson’s correlation coefficient.
Changes in all the clinical parameters from baseline to 2 weeks
after admission were subjected to the paired t-test. The relation-
ships between the changes in plasma XOR activity and those in
other clinical parameters were calculated using Pearson’s corre-
lation coefficient. In all cases, P-values <0.05 were considered
to be significant. To identify parameters that independently
related to the baseline plasma XOR activity or changes in
plasma XOR activity during hospitalization, those with P-values
<0.05 in the simple regression analysis were entered into a for-
ward-backward stepwise multiple regression analysis as inde-
pendent variables. All analyses were carried out with the JMP
Statistical Discovery Software 14.0 (SAS Institute, Cary, NC,
USA).
RESULTS
Baseline characteristics of patients with type 2 diabetes
mellitus
The baseline characteristics of patients with type 2 diabetes
mellitus (10 men/18 women) enrolled in the present study are
shown in Table 1. Briefly, the mean age, BMI and HbA1c were
63.4 years, 26.8 kg/m2 and 9.2%, respectively. The median
duration of diabetes was 15 years (IQR 8–20.8 years), and there
was no newly diagnosed patient. Complications of hyperten-
sion, dyslipidemia and CVD were observed in 68, 82 and 25%
of the participants, respectively. The median value of plasma
XOR activity was 83.1 pmol/h/mL (IQR 31.6–254 pmol/h/mL),
with a wide range of 14.4–1150 pmol/h/mL.
Clinical parameters correlated with plasma XOR activity at
admission
We examined the relationships between plasma XOR activity
and each of the clinical parameters at the time of admission.
As shown in Table S1, in the univariate analysis, plasma XOR
activity positively correlated with bodyweight, BMI, WC, C-
peptide, liver enzymes (AST, ALT and γ-GTP), estimated
glomerular filtration rate and hs-CRP, and negatively with age.
No significant correlation was found between the XOR activity
and serum uric acid levels. Next, a stepwise multiple regression
was carried out to determine the parameters that were indepen-
dently related to the baseline plasma XOR activity. To avoid
the problem of multicollinearity, BMI and AST were selected
into the model instead of bodyweight, WC and ALT. As a
result, serum AST was identified as the only significant factor
associated with plasma XOR activity (Table S2a). When ALT
was added into the model instead of AST, it was also the only
independent factor for the baseline plasma XOR activity (Table
S2b). Among 16 out of 28 patients who were not treated with
long-acting insulin, HOMA-IR positively correlated with plasma
XOR activity (R = 0.59, P = 0.02). However, this association
was no longer statistically significant after adjustment for AST
(P = 0.06) or ALT (P = 0.38).
Relationships between changes in plasma XOR activity and
those in other clinical parameters after 2 weeks of treatment
during hospitalization
As shown in Table 2, 2 weeks of treatment during hospitaliza-
tion resulted in an average weight loss of 1.3 kg (P < 0.0001),
which was associated with significant improvements in multiple
clinical parameters, including fasting plasma glucose, HbA1c,
TG, γ-GTP and hs-CRP. During the same period, plasma XOR
activity was also modestly, but significantly, decreased
(P = 0.041). A tendency of decrease in serum AST and ALT
was also observed.
We then assessed the relationship between changes in each
clinical parameter and those in plasma XOR activity 2 weeks
after admission. As shown in Table 3, in the univariate analysis,
changes in the log plasma XOR activity positively correlated
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with those in low-density lipoprotein cholesterol, log-AST, log-
ALT and log-adiponectin, whereas no correlation was found
between the changes in log plasma XOR activity and those in
BMI, glycemic parameters (fasting blood glucose, HbA1c and
glycoalbumin) and plasma purine metabolites (uric acid, log
hypoxanthine and log xanthine). The stepwise multiple regres-
sion analysis showed that the changes in log-AST (ΔLog-AST)
was the sole factor correlating changes in the log plasma XOR
activity (ΔLog-XOR), when ΔLog-AST instead of ΔLog-ALT
was entered into the model because of its higher correlation
coefficient with ΔLog-XOR (Table 4). As shown in Figure 1a,
ΔLog-AST was strongly and positively correlated with ΔLog-
XOR (R = 0.82, P < 0.0001).
Table 2 | Changes in clinical parameters from admission to 2 weeks
after treatment for diabetes
Clinical parameters Adm Post P-value
BW (kg) 67.8 – 14.1 66.5 – 13.7 <0.0001
BMI (kg/m2) 26.8 – 5.3 26.3 – 5.1 <0.0001
sBP (mmHg) 131 – 18 124 – 12 0.085
dBP (mmHg) 76 – 17 75 – 12 0.817
FPG (mg/dL) 147.9 – 47.4 109 – 19 <0.0001
C-peptide (ng/mL) 1.62 – 0.99 1.41 – 0.80 0.146
HbA1c (%) 9.2 – 2.1 8.5 – 1.7 <0.0001
HbA1c (mmol/mol) 77 – 23 69 – 18 <0.0001
GA (%) 23.7 – 5.9 19.4 – 3.5 <0.0001
T-cho (mg/dL) 199.8 – 62.5 158.1 – 30.3 <0.0001
LDL-cho (mg/dL) 120.3 – 50.1 88.3 – 28.8 <0.0001
HDL-cho (mg/dL) 53.4 – 12.3 49.6 – 10.9 0.003
Log-TG (mg/dL) 4.85 – 0.61 4.58 – 0.41 0.001
Log-AST (IU/L) 3.16 – 0.40 3.07 – 0.31 0.092
Log-ALT (IU/L) 3.15 – 0.61 3.04 – 0.53 0.085
Log-γ-GTP (IU/L) 3.42 – 0.65 3.19 – 0.65 <0.0001
Log-LDH (IU/L) 5.20 – 0.21 5.13 – 0.20 0.006
Creatinine (mg/dL) 0.75 – 0.23 0.79 – 0.24 0.042
eGFR (mL/min/1.73 m2) 72.0 – 21.2 68.1 – 18.6 0.018
UA (mg/dL) 5.6 – 1.2 5.4 – 1.0 0.161
Log-Xan (μmol/L) −0.50 – 0.35 −0.48 – 0.59 0.894
Log-HX (μmol/L) −0.008 – 0.69 −0.058 – 0.59 0.745
Log-XOR (pmol/h/mL) 4.5 – 1.2 4.3 – 1.0 0.041
Log-hs-CRP (mg/dL) −2.50 – 1.06 −2.85 – 0.71 0.047
Log-adiponectin (μg/mL) 1.76 – 0.67 1.68 – 0.66 0.037
Log-AcAc (μmol/L) 4.12 – 0.67 4.07 – 0.70 0.713
Log-3-OHBA (μmol/L) 4.60 – 0.86 4.71 – 0.82 0.487
Data are presented as the means – standard deviation. γ-GTP, γ-glu-
tamyl transpeptidase; 3-OHBA, 3-hydroxybutyrate; AcAc, acetoacetate;
Adm, admission; ALT, alanine transaminase; AST, aspartate transaminase;
BMI, body mass index; BW, bodyweight; dBP, diastolic blood pressure;
eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose;
GA, glycoalbumin; HDL-cho, high-density lipoprotein cholesterol; hs-
CRP, high sensitivity C-reactive protein; HX, hypoxanthine; LDH, lactate
dehydrogenase; LDL-cho, low-density lipoprotein cholesterol; Post,
2 weeks after treatment during hospitalization; sBP, systolic blood pres-
sure; T-cho, total cholesterol; TG, triglyceride; UA, uric acid; Xan, xan-
thine; XOR, xanthine oxidoreductase.
Table 1 | Baseline clinical characteristics of patients with type 2 diabetes
Clinical parameters
n (males/females) 28 (10/18)
Age (years) 63.4 – 11
BW (kg) 67.8 – 14.1
BMI (kg/m2) 26.8 – 5.3
WC (cm) 98.9 – 10.5
sBP (mmHg) 131.8 – 18.4
dBP (mmHg) 76.6 – 16.9
FPG (mg/dL) 147.9 – 47.4
C-peptide (ng/mL) 1.62 – 0.99
HbA1c (%) 9.2 – 2.1
HbA1c (mmol/mol) 77 – 23
GA (%) 23.7 – 5.9
T-cho (mg/dL) 199.8 – 62.5
LDL-cho (mg/dL) 120.3 – 50.1
HDL-cho (mg/dL) 53.4 – 12.3
TG (mg/dL) 125 (75.3–232.3)
AST (IU/L) 22 (17–27)
ALT (IU/L) 21.5 (15.5–39.3)
γ-GTP (IU/L) 26.5 (18.3–45.8)
LDH (IU/L) 189.5 (156.0–208.8)
Creatinine (mg/dL) 0.75 – 0.23
eGFR (mL/min/1.73 m2) 72.0 – 21.2
UA (mg/dL) 5.6 – 1.2
Xan (μmol/L) 0.63 (0.45–0.83)
HX (μmol/L) 1.01 (0.55–1.48)
XOR activity (pmol/h/mL) 83.1 (31.6–254)
hs-CRP (mg/dL) 0.05 (0.04–0.11)
Adiponectin (μg/mL) 6.6 (4.1–8.9)
AcAc (μmol/L) 63.5 (36.5–97.8)
3-OHBA (μmol/L) 93.5 (45.3–195.8)
CCA max IMT (mm) 1.9 – 1.0
baPWV (m/s) 1753 – 280
Duration of diabetes (years) 15 (8–20.8)
Glucose-lowering agents
(SU/BG/TZD/DPP-4i/α-GI/SGLT-2i/GLP-1 RA/insulin) 8/12/1/9/2/6/6/14
Smoking habit (current/past/non) 2/12/14
Complication of hypertension 19 (68%)
Complication of dyslipidemia 23 (82%)
Complication of CVD 7 (25%)
Data are presented as the mean – standard deviation, median (in-
terquartile range) or the number of participants (%). α-GI, α-glucosidase
inhibitor; γ-GTP, γ-glutamyl transpeptidase; 3-OHBA, 3-hydroxybutyrate;
AcAc, acetoacetate; ALT, alanine transaminase; AST, aspartate transami-
nase; BG, biguanide; BMI, body mass index; BW, bodyweight; CCA, com-
mon carotid artery; CVD, cardiovascular disease; dBP, diastolic blood
pressure; DPP-4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated
glomerular filtration rate; FPG, fasting plasma glucose; GA, glycoalbumin;
GLP-1 RA, glucagon-like peptide-1 receptor agonist; HDL-cho, high-den-
sity lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein;
HX, hypoxanthine; IMT, intima-media thickness; LDH, lactate dehydroge-
nase; LDL-cho, low-density lipoprotein cholesterol; PWV, brachial-ankle
pulse wave velocity; sBP, systolic blood pressure; SGLT-2i, sodium–glu-
cose cotransporter 2 inhibitor; SU, sulfonylurea; T-cho, total cholesterol;
TG, triglyceride; TZD, thiazolidine; UA; uric acid; WC, waist circumference;
Xan, xanthine; XOR, xanthine oxidoreductase.
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Because plasma XOR activity levels at admission varied
widely among the patients, we divided the patients into two
groups according to their baseline plasma XOR activity, higher
or lower than the median value, and examined changes in
plasma XOR and serum AST separately for each group. As
shown in Figure 1b, plasma XOR activity was markedly
decreased in patients with high baseline XOR activity, and was
associated with significant reductions in serum AST. On the
contrary, no significant changes were observed in these two
parameters in the low XOR group (Figure 1b).
Plasma XOR activity in control participants without diabetes
Finally, 29 healthy volunteers (20 men/9 women) were exam-
ined to investigate whether such associations between plasma
XOR activity and liver enzymes also emerge for individuals
without diabetes. Mean age, BMI and HbA1c were 42.4 years,
22.6 kg/m2 and 5.4%, respectively (Table S3). The median
plasma XOR activity was 35.6 pmol/h/mL (IQR 24.4–-
69.1 pmol/h/mL), ranging from 8.67 to 173 pmol/h/mL. The
plasma XOR activity levels were higher in men than in women,
and positively correlated with bodyweight, BMI, WC, HOMA-
IR, liver enzymes (AST, ALT and γ-GTP) and hs-CRP (Table
S4). Plasma purine metabolites, including uric acid and xan-
thine, also positively correlated with the plasma XOR activity in
these participants. However, the stepwise multiple regression
analysis showed that just three parameters – namely, sex, serum
ALT and γ-GTP levels – were significant independent predic-
tors of the plasma XOR activity, when ALT instead of AST
was incorporated into the model because of its higher correla-
tion coefficient with plasma XOR (Table S5). Among these,
ALT had the strongest correlation with the XOR activity
(standard β = 0.664, P < 0.0001).
DISCUSSION
The main results of the present study of Japanese inpatients
with type 2 diabetes mellitus are as follows: (i) cross-sectionally,
the serum levels of liver transaminases (AST and ALT) were
identified as significant factors correlating with the baseline
plasma XOR activity; (ii) after 2 weeks of treatment during
hospitalization, plasma XOR activity significantly decreased,
particularly in patients with initially high plasma XOR; and (iii)
changes in plasma XOR activity were strongly and indepen-
dently associated with changes in serum AST.
To our knowledge, this is the first study to assess plasma
XOR activity cross-sectionally and across treatments for patients
with type 2 diabetes mellitus. The baseline plasma XOR activity
was correlated with age, BMI, C-peptide, hs-CRP and serum
liver enzymes (AST, ALT and γ-GTP) in a simple regression
analysis. Similar findings were recently reported in a cross-sec-
tional study on 60 Japanese patients with type 2 diabetes melli-
tus and metabolic syndrome, in which plasma xanthine oxidase
activity correlated with BMI, HOMA-IR and liver transami-
nases19. In contrast, a subsequent stepwise multivariate analysis
in the present study showed that the only independent
Table 3 | Correlations between changes in plasma xanthine





























γ-GTP, γ-glutamyl transpeptidase; 3-OHBA, 3-hydroxybutyrate; AcAc, ace-
toacetate; ALT, alanine transaminase; AST, aspartate transaminase; BMI,
body mass index; BW, bodyweight; dBP, diastolic blood pressure; eGFR,
estimated glomerular filtration rate; FPG, fasting plasma glucose; GA,
glycoalbumin; HDL-cho, high-density lipoprotein cholesterol; hs-CRP,
high sensitivity C-reactive protein; HX, hypoxanthine; LDH, lactate dehy-
drogenase; LDL-cho, low-density lipoprotein cholesterol; sBP, systolic
blood pressure; T-cho, total cholesterol; TG, triglyceride; UA, uric acid;
Xan, xanthine; XOR, xanthine oxidoreductase.
Table 4 | Multiple stepwise regression analysis of changes in clinical
parameters associated with those in plasma XOR activity during
hospitalization
Clinical parameters Multivariate
β SE Std β P-value
ΔLDL-cho −0.0009 0.002 −0.050 0.716
ΔLog-AST 2.059 0.282 0.820 <0.0001
ΔLog-adiponectin −0.005 0.487 −0.002 0.991
Adjusted R2 0.659
Parameters shown in boldface were statistically significant. AST, aspar-
tate transaminase; LDL-cho, low-density lipoprotein cholesterol.
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predictors of plasma XOR in patients with type 2 diabetes mel-
litus were serum AST and ALT, with similar results being
obtained for control participants without diabetes (Tables S2,
S5). Additionally, a 2-week treatment for diabetes was associ-
ated with a significant decrease in plasma XOR activity, partic-
ularly in patients with high baseline XOR levels, and this
change was only and strongly associated with that in AST
(Tables 3,4). Not only HbA1c, but also glycoalbumin, which
reflects short-term glycemic control (during the last 2–3 weeks),
improved during hospitalization. However, there was no signifi-
cant correlation between the changes in these glycemic parame-
ters and those in plasma XOR, suggesting that changes in
glycemic control within a short period, at least 2 weeks in the
present study, were not associated with the decrease in XOR
activity. Taken together, caloric restriction and improved glyce-
mic control under hospitalized conditions might have amelio-
rated liver function, which was associated with decreases in
plasma XOR activity.
To date, few studies have evaluated changes in the XOR
activity. It was recently reported that, in a population-based
cohort, an annual change in plasma XOR activity was indepen-
dently associated with a change in bodyweight, as well as that
in liver enzymes20. In the present study, changes in bodyweight
and BMI did not correlate with those in plasma XOR activity.
A possible explanation for this difference might be that the
absolute change in bodyweight in the present study (the mean
value of −1.3 kg) was small and might have little association
with plasma XOR activity. We previously reported XOR
expression and uric acid secretion in murine adipose tissue,
both of which were elevated in obese mice21. In contrast, in a
subsequent study, we found that the expression levels of the
XOR messenger ribonucleic acid were far lower in the human
adipose tissue than in the liver and small intestine. Conse-
quently, XOR activity in human adipose tissue was markedly
lower than that in murine adipose tissue, resulting in the secre-
tion of more hypoxanthine from human adipose tissue than
xanthine and uric acid12. In addition, a recent study showed
that a significant rise in plasma XOR activity in high-fat-in-
duced obesity was almost canceled by hepatocyte-specific abla-
tion of XOR in mice, suggesting a limited contribution of
adipose tissue to the circulating XOR levels in mice as well22.
Previous findings and the present results collectively show
that a large proportion of the XOR protein in the human
bloodstream is derived from the continuous leakage of hepatic
XOR, but not from adipocytes. Furthermore, plasma XOR
activity might be elevated in the background of liver diseases,
such as non-alcoholic fatty liver disease (NAFLD), often associ-
ated with obesity and diabetes23. A number of clinical investiga-
tions have shown that NAFLD increases the risk of CVD,
independent of established cardiovascular risk factors24–26.
Although the underlying mechanism for this association is still






























































Figure 1 | Relationship between changes in serum aspartate aminotransferase (AST) with those in plasma xanthine oxidoreductase (XOR) activity
during 2 weeks of hospitalization. (a) Pearson’s correlation coefficient was used to examine the relationship between changes in serum AST and
those in plasma XOR activity (P < 0.0001, R = 0.82). (b) Patients were divided into two groups according to their baseline plasma XOR activity
levels, higher or lower than the median value (83.1 pmol/h/mL). Changes in plasma XOR activity and serum AST from admission (Adm) to 2 weeks
after treatment during hospitalization (Post) are shown for each group. Data are the mean – standard deviation. **P < 0.01, ***P < 0.001. NS, not
significant.
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lipid metabolism, the gut microbiome and the pro-inflamma-
tory state in NAFLD patients are considered to play important
roles in the pathogenesis of atherosclerosis27–29. In addition to
these, an excess XOR release into the systemic circulation due
to chronic hepatic injury might participate in the cross-talk
between NAFLD and CVD progression. Further clinical and
experimental studies are required to clarify whether increased
plasma XOR activity per se could be involved in atherosclerosis
associated with type 2 diabetes mellitus.
Plasma XOR activity in patients with type 2 diabetes mellitus
(median value of 83.1 pmol/h/mL) was relatively high com-
pared with that previously reported in the general population
(median value of 36 pmol/h/mL)15, in which XOR activity
levels were assessed by the same method. We also found that
the value in individuals with diabetes was significantly higher
than that in our group without diabetes (median value of
35.6 pmol/h/mL; P = 0.002), and the statistical significance
between the two groups persisted even after adjustment for sex,
age, BMI, TG, AST, ALT and HbA1c (P = 0.004), suggesting
that pathogenesis of diabetes per se might be associated with
increased plasma XOR activity. However, because of clear dif-
ferences in baseline characteristics of the type 2 diabetes melli-
tus patients and the healthy volunteers (Tables 1,S3), further
large-scale case–control studies are required to confirm this pre-
liminary finding. Previous studies in rodents have shown that
inflammatory mediators including bacterial lipopolysaccharide
and interleukin-1β upregulated XOR expression in liver and
lung tissues30,31. As such, in addition to leakage from damaged
hepatocytes, the pro-inflammatory state in patients with dia-
betes might relate to increased plasma XOR activity.
The present study has several limitations. Although patients
taking antihyperuricemic drugs were excluded from the present
study, some glucose-lowering agents, such as selective sodium–-
glucose cotransporter 2 inhibitors, might affect bodyweight,
serum liver enzymes and plasma uric acid levels32,33. The num-
ber of patients was relatively small to carry out a multivariate
analysis and to identify clinical parameters that had weaker
associations with plasma XOR activity. Although no study par-
ticipant had hepatitis B or C, examinations other than blood
tests were not undertaken to assess the etiology and severity of
liver dysfunction. Therefore, it currently remains unclear
whether the pathological progression of liver damage affects
plasma XOR activity, independent of the serum liver transami-
nase levels.
In conclusion, the present results showed a close relationship
between plasma XOR activity and circulating levels of liver
transaminases in patients with type 2 diabetes mellitus, cross-
sectionally and across hospitalized treatment, suggesting that
plasma XOR reflects liver damage in patients with diabetes.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.
Table S1 | Correlations between plasma xanthine oxidoreductase activity and clinical parameters in patients with type 2 diabetes at
admission.
Table S2 | Multiple stepwise regression analysis of clinical parameters associated with the baseline plasma xanthine oxidoreductase
activity.
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Table S3 | Clinical characteristics in control participants without diabetes.
Table S4 | Correlations between the plasma xanthine oxidoreductase activity and clinical parameters in control participants without
diabetes.
Table S5 | Multiple stepwise regression analysis of clinical parameters associated with the plasma xanthine oxidoreductase activity
in control participants without diabetes.
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